| Identification | Back Directory | [Name]
3-Pyridazinecarboxamide, 1,4-dihydro-N-[4-[[7-[[7-(hydroxyamino)-7-oxoheptyl]oxy]-6-methoxy-4-quinolinyl]oxy]phenyl]-4-oxo-1-phenyl- | [CAS]
2740495-53-6 | [Synonyms]
c-Met/HDAC-IN-2
3-Pyridazinecarboxamide, 1,4-dihydro-N-[4-[[7-[[7-(hydroxyamino)-7-oxoheptyl]oxy]-6-methoxy-4-quinolinyl]oxy]phenyl]-4-oxo-1-phenyl- | [Molecular Formula]
C34H33N5O7 | [MOL File]
2740495-53-6.mol | [Molecular Weight]
623.66 |
| Hazard Information | Back Directory | [Uses]
c-Met/HDAC-IN-2 is a highly potent c-Met and HDAC dual inhibitor with IC50s of 18.49 nM and 5.40 nM for HDAC1 and c-Met, respectively. c-Met/HDAC-IN-2 has antiproliferative activities against certain cancer cell lines. c-Met/HDAC-IN-2 can cause G2/M-phase arrest and induce apoptosis in HCT-116. c-Met/HDAC-IN-2 can be used for researching anti-cancer resistance[1]. | [IC 50]
HDAC1: 18.49 nM (IC50) | [References]
[1] Hu H, Chen F, Dong Y, et al. Discovery of Novel c-Mesenchymal-Epithelia transition factor and histone deacetylase dual inhibitors. Eur J Med Chem. 2020;204:112651. DOI:10.1016/j.ejmech.2020.112651 |
|
|